Dr. Andtbacka on T-VEC Plus Ipilimumab in Unresected Melanoma

Video

In Partnership With:

Robert H. I. Andtbacka, MD, CM, from Intermountain Healthcare and Huntsman Cancer Institute, discusses the safety and efficacy of T-VEC in combination with ipilimumab in patients with previously untreated, unresected stage IIIB-IV melanoma.

Robert H. I. Andtbacka, MD, CM, a surgeon and investigator with Intermountain Healthcare and Huntsman Cancer Institute, discusses the safety and efficacy of talimogene laherparepvec (T-VEC) in combination with ipilimumab in patients with previously untreated, unresected stage IIIB-IV melanoma.

In a phase Ib study, 18 patients received treatment with the combination of T-VEC and the CTLA-4 inhibitor ipilimumab. Overall, this study demonstrated promising efficacy without inducing dose-limiting toxicity, with most of the toxicity experienced by patients associated with ipilimumab rather than T-VEC, Andtbacka explains. Overall, grade 3/4 adverse events occurred in 32% of patients, with the most common T-VEC-related event being pyrexia.

The overall response rate for ipilimumab plus T-VEC was 56%, with 33% of patients experiencing a complete response. The disease control rate was 72%. The ongoing phase Ib study is moving into a phase II component that will randomize patients to ipilimumab alone or in combination with T-VEC, explains Andtbacka. This study is currently recruiting patients (NCT01740297).

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD